Skip to main content
Top
Published in: Cellular Oncology 5/2019

01-10-2019 | Original Paper

Molecular profiling of anastatic cancer cells: potential role of the nuclear export pathway

Authors: Mahendra Seervi, S. Sumi, Aneesh Chandrasekharan, Abhay K. Sharma, T. R. SanthoshKumar

Published in: Cellular Oncology | Issue 5/2019

Login to get access

Abstract

Purpose

Anastasis is newly discovered process by which cells recover from late-stage apoptosis upon removal of a death stimulus. Recent reports suggest that cells may recover, even after the initiation of mitochondrial outer-membrane permeabilization (MOMP) and caspase activation. Here, we specifically studied the reversibility of late-stage apoptosis in cervical (HeLa) and breast (MDA-MB-231) cancer cells in relation to the extent of MOMP (limited or widespread). In addition, we explored the molecular factors involved in the anastatic process.

Methods

The extent of MOMP was assessed using time lapse confocal microscopic imaging, considering mitochondrial cytochrome c-GFP release as a marker for MOMP. Anastatic cells were generated by specifically recovering late-stage apoptotic (annexin V/PI positive) cervical and breast cancer cells. Molecular signaling events involved in death reversal were assessed using LC-MS/MS and qRT-PCR. Targeted chemical inhibition and shRNA-based gene silencing studies were employed to explore the role of the nuclear export pathway in anastasis and increased oncogenicity.

Results

Time-lapse imaging of drug-treated Cyt-c-GFP expressing cancer cells revealed cell recovery despite widespread MOMP. A few recovered anastatic cells were noted and these were found to proliferate through a selection-type of survival. They showed increased drug-resistance, migration and invasive potential compared to non-anastatic cancer cells. Network analysis using 49 proteins uniquely expressed in anastatic cells indicated upregulation of nuclear export/import, redox and Ras signaling pathways in both HeLa and MDA-MB-231 anastatic cells, indicating common molecular mechanisms in different cell types. Inhibition of XPO1 significantly reduced the recovery of apoptotic cells and abrogated acquired oncogenic transformation in the anastatic cancer cells.

Conclusions

Our study indicates that cancer cells can revert from apoptosis even after the induction of widespread MOMP. We noted a significant role of the nuclear-export pathway in the anastatic process of cancer cells. Inhibition of anastasis through the nuclear export pathway may be a potential therapeutic strategy for targeting drug-resistance, metastasis and recurrence problems during cancer treatment.
Appendix
Available only for authorised users
Literature
1.
go back to reference A.R. Delbridge, L.J. Valente, A. Strasser, The role of the apoptotic machinery in tumor suppression. Cold Spring Harb. Perspect. Biol. 4, a008789 (2012)CrossRefPubMedPubMedCentral A.R. Delbridge, L.J. Valente, A. Strasser, The role of the apoptotic machinery in tumor suppression. Cold Spring Harb. Perspect. Biol. 4, a008789 (2012)CrossRefPubMedPubMedCentral
2.
go back to reference S. Baig, I. Seevasant, J. Mohamad, A. Mukheem, H.Z. Huri, T. Kamarul, Potential of apoptotic pathway-targeted cancer therapeutic research: Where do we stand? Cell Death Dis. 7, e2058 (2017)CrossRef S. Baig, I. Seevasant, J. Mohamad, A. Mukheem, H.Z. Huri, T. Kamarul, Potential of apoptotic pathway-targeted cancer therapeutic research: Where do we stand? Cell Death Dis. 7, e2058 (2017)CrossRef
3.
go back to reference S. Gupta, G.E. Kass, E. Szegezdi, B. Joseph, The mitochondrial death pathway: A promising therapeutic target in diseases. J. Cell. Mol. Med. 13, 1004–1033 (2009)CrossRefPubMedPubMedCentral S. Gupta, G.E. Kass, E. Szegezdi, B. Joseph, The mitochondrial death pathway: A promising therapeutic target in diseases. J. Cell. Mol. Med. 13, 1004–1033 (2009)CrossRefPubMedPubMedCentral
5.
go back to reference R. Khosravi-Far, Death receptor signals to the mitochondria. Canc Biol Ther 3, 1051–1057 (2004)CrossRef R. Khosravi-Far, Death receptor signals to the mitochondria. Canc Biol Ther 3, 1051–1057 (2004)CrossRef
6.
go back to reference H.L. Tang, H.M. Tang, K.H. Mak, S. Hu, S.S. Wang, K. M. Wong, C. S. Wong, H.Y. Wu, H.T. Law, K. Liu, C.C. Talbo Jr, W.K. Lau, D. J. Montell, M.C. Fung, Cell survival, DNA damage, and oncogenic transformation after a transient and reversible apoptotic response. Mol. Biol. Cell 23, 2240–2252 (2012) H.L. Tang, H.M. Tang, K.H. Mak, S. Hu, S.S. Wang, K. M. Wong, C. S. Wong, H.Y. Wu, H.T. Law, K. Liu, C.C. Talbo Jr, W.K. Lau, D. J. Montell, M.C. Fung, Cell survival, DNA damage, and oncogenic transformation after a transient and reversible apoptotic response. Mol. Biol. Cell 23, 2240–2252 (2012)
7.
go back to reference X. Liu, Y. He, F. Li, Q. Huang, T.A. Kato, R.P. Hall, C.Y. Li, Caspase-3 promotes genetic instability and carcinogenesis. Mol. Cell 58, 284–296 (2015)CrossRefPubMedPubMedCentral X. Liu, Y. He, F. Li, Q. Huang, T.A. Kato, R.P. Hall, C.Y. Li, Caspase-3 promotes genetic instability and carcinogenesis. Mol. Cell 58, 284–296 (2015)CrossRefPubMedPubMedCentral
8.
go back to reference A.X. Ding, G. Sun, Y.G. Argaw, J.O. Wong, S. Easwaran, D.J. Montell, CasExpress reveals widespread and diverse patterns of cell survival of caspase-3 activation during development in vivo. Elife 5, e10936 (2016)CrossRefPubMedPubMedCentral A.X. Ding, G. Sun, Y.G. Argaw, J.O. Wong, S. Easwaran, D.J. Montell, CasExpress reveals widespread and diverse patterns of cell survival of caspase-3 activation during development in vivo. Elife 5, e10936 (2016)CrossRefPubMedPubMedCentral
9.
go back to reference G. Ichim, J. Lopez, S.U. Ahmed, N. Muthalagu, E. Giampazolias, M.E. Delgado, M. Haller, J.S. Riley, S.M. Mason, D. Athineos, M.J. Parsons, B. van de Kooij, L. Bouchier-Hayes, A.J. Chalmers, R.W. Rooswinkel, A. Oberst, K. Blyth, M. Rehm, D.J. Murphy, S.W.G. Tait, Limited mitochondrial permeabilization causes DNA damage and genomic instability in the absence of cell death. Mol. Cell 57, 860–872 (2015)CrossRefPubMedPubMedCentral G. Ichim, J. Lopez, S.U. Ahmed, N. Muthalagu, E. Giampazolias, M.E. Delgado, M. Haller, J.S. Riley, S.M. Mason, D. Athineos, M.J. Parsons, B. van de Kooij, L. Bouchier-Hayes, A.J. Chalmers, R.W. Rooswinkel, A. Oberst, K. Blyth, M. Rehm, D.J. Murphy, S.W.G. Tait, Limited mitochondrial permeabilization causes DNA damage and genomic instability in the absence of cell death. Mol. Cell 57, 860–872 (2015)CrossRefPubMedPubMedCentral
12.
go back to reference I. Vermes, C. Haanen, H. Steffens-Nakken, C. Reutellingsperger, A novel assay for apoptosis flow cytometric detection of phosphatidylserine expression on early apoptotic cells using fluorescein labelled annexin V. J. Immunol. Methods 184, 39–51 (1995)CrossRefPubMed I. Vermes, C. Haanen, H. Steffens-Nakken, C. Reutellingsperger, A novel assay for apoptosis flow cytometric detection of phosphatidylserine expression on early apoptotic cells using fluorescein labelled annexin V. J. Immunol. Methods 184, 39–51 (1995)CrossRefPubMed
13.
go back to reference A.L. Hong, Y.Y. Tseng, G.S. Cowley, O. Jonas, J.H. Cheah, B.D. Kynnap, M.B. Doshi, C. Oh, S.C. Meyer, A.J. Church, S. Gill, C.M. Bielski, P. Keskula, A. Imamovic, S. Howell, G.V. Kryukov, P.A. Clemons, A. Tsherniak, F. Vazquez, B.D. Crompton, A.F. Shamji, C. Rodriguez-Galindo, K.A. Janeway, C.W.M. Roberts, K. Stegmaier, P. van Hummelen, M.J. Cima, R.S. Langer, L.A. Garraway, S.L. Schreiber, D.E. Root, W.C. Hahn, J.S. Boehm, Integrated genetic and pharmacologic interrogation of rare cancers. Nat. Commun. 7, 11987 (2016)CrossRefPubMedPubMedCentral A.L. Hong, Y.Y. Tseng, G.S. Cowley, O. Jonas, J.H. Cheah, B.D. Kynnap, M.B. Doshi, C. Oh, S.C. Meyer, A.J. Church, S. Gill, C.M. Bielski, P. Keskula, A. Imamovic, S. Howell, G.V. Kryukov, P.A. Clemons, A. Tsherniak, F. Vazquez, B.D. Crompton, A.F. Shamji, C. Rodriguez-Galindo, K.A. Janeway, C.W.M. Roberts, K. Stegmaier, P. van Hummelen, M.J. Cima, R.S. Langer, L.A. Garraway, S.L. Schreiber, D.E. Root, W.C. Hahn, J.S. Boehm, Integrated genetic and pharmacologic interrogation of rare cancers. Nat. Commun. 7, 11987 (2016)CrossRefPubMedPubMedCentral
14.
go back to reference M.R. Dalman, A. Deeter, G. Nimishakavi, Z.H. Duan, Fold change and p-value cutoffs significantly alter microarray interpretations. BMC Bioinformatics 13, S11 (2012)CrossRefPubMedPubMedCentral M.R. Dalman, A. Deeter, G. Nimishakavi, Z.H. Duan, Fold change and p-value cutoffs significantly alter microarray interpretations. BMC Bioinformatics 13, S11 (2012)CrossRefPubMedPubMedCentral
15.
go back to reference K. Raza, A. Mishra, A novel anticlustering filtering algorithm for the prediction of genes as a drug target. Am J Biomed Eng 2, 206–211 (2012)CrossRef K. Raza, A. Mishra, A novel anticlustering filtering algorithm for the prediction of genes as a drug target. Am J Biomed Eng 2, 206–211 (2012)CrossRef
16.
go back to reference P.D. Thomas, M.J. Campbell, A. Kejariwal, H. Mi, B. Karlak, R. Daverman, K. Diemer, A. Muruganujan, A. Narechania, PANTHER: A library of protein families and subfamilies indexed by function. Genome Res. 13, 2129–2141 (2003)CrossRefPubMedPubMedCentral P.D. Thomas, M.J. Campbell, A. Kejariwal, H. Mi, B. Karlak, R. Daverman, K. Diemer, A. Muruganujan, A. Narechania, PANTHER: A library of protein families and subfamilies indexed by function. Genome Res. 13, 2129–2141 (2003)CrossRefPubMedPubMedCentral
17.
go back to reference D.W. Huang, B.T. Sherman, R.A. Lempicki, Systematic and integrative analysis of large gene lists using DAVID bioinformatics resources. Nat. Protoc. 4, 44 (2008)CrossRef D.W. Huang, B.T. Sherman, R.A. Lempicki, Systematic and integrative analysis of large gene lists using DAVID bioinformatics resources. Nat. Protoc. 4, 44 (2008)CrossRef
18.
go back to reference L.J. Jensen, M. Kuhn, M. Stark, S. Chaffron, C. Creevey, J. Muller, T. Doerks, P. Julien, A. Roth, M. Simonovic, P. Bork, STRING 8-a global view on proteins and their functional interactions in 630 organisms. Nucleic Acids Res. 37(suppl_1), D412–D416 (2008)PubMedPubMedCentral L.J. Jensen, M. Kuhn, M. Stark, S. Chaffron, C. Creevey, J. Muller, T. Doerks, P. Julien, A. Roth, M. Simonovic, P. Bork, STRING 8-a global view on proteins and their functional interactions in 630 organisms. Nucleic Acids Res. 37(suppl_1), D412–D416 (2008)PubMedPubMedCentral
19.
go back to reference M. Seervi, J. Joseph, P.K. Sobhan, B.C. Bhavya, T.R. Santhoshkumar, Essential requirement of cytochrome c release for caspase activation by procaspase-activating compound defined by cellular models. Cell Death Dis. 2, e207 (2011)CrossRefPubMedPubMedCentral M. Seervi, J. Joseph, P.K. Sobhan, B.C. Bhavya, T.R. Santhoshkumar, Essential requirement of cytochrome c release for caspase activation by procaspase-activating compound defined by cellular models. Cell Death Dis. 2, e207 (2011)CrossRefPubMedPubMedCentral
20.
go back to reference J.C. Goldstein, C. Munoz-Pinedo, J.E. Ricci, S.R. Adams, A. Kelekar, M. Schuler, R.Y. Tsien, D.R. Green, Cytochrome c is released in a single step during apoptosis. Cell Death Differ. 12, 453–462 (2005)CrossRefPubMed J.C. Goldstein, C. Munoz-Pinedo, J.E. Ricci, S.R. Adams, A. Kelekar, M. Schuler, R.Y. Tsien, D.R. Green, Cytochrome c is released in a single step during apoptosis. Cell Death Differ. 12, 453–462 (2005)CrossRefPubMed
21.
go back to reference N.V. Krakhmal, M.V. Zavyalova, E.V. Denisov, S.V. Vtorushin, V.M. Perelmuter, Cancer invasion: Patterns and mechanisms. Acta Nat. 7, 17–28 (2015)CrossRef N.V. Krakhmal, M.V. Zavyalova, E.V. Denisov, S.V. Vtorushin, V.M. Perelmuter, Cancer invasion: Patterns and mechanisms. Acta Nat. 7, 17–28 (2015)CrossRef
22.
go back to reference T.M. Penning, J.E. Drury, Human aldo-keto reductases: Function, gene regulation, and single nucleotide polymorphisms. Arch. Biochem. Biophys. 464, 241–250 (2007)CrossRefPubMedPubMedCentral T.M. Penning, J.E. Drury, Human aldo-keto reductases: Function, gene regulation, and single nucleotide polymorphisms. Arch. Biochem. Biophys. 464, 241–250 (2007)CrossRefPubMedPubMedCentral
23.
go back to reference C.Y. Chiang, C.C. Pan, H.Y. Chang, M.D. Lai, T.S. Tzai, Y.S. Tsai, P. Ling, H.S. Liu, B.F. Lee, H.L. Cheng, C.L. Ho, S.H. Chen, N.H. Chow, SH3BGRL3 protein as a potential prognostic biomarker for urothelial carcinoma: A novel binding partner of epidermal growth factor receptor. Clin. Cancer Res. 21, 5601–5611 (2015)CrossRefPubMed C.Y. Chiang, C.C. Pan, H.Y. Chang, M.D. Lai, T.S. Tzai, Y.S. Tsai, P. Ling, H.S. Liu, B.F. Lee, H.L. Cheng, C.L. Ho, S.H. Chen, N.H. Chow, SH3BGRL3 protein as a potential prognostic biomarker for urothelial carcinoma: A novel binding partner of epidermal growth factor receptor. Clin. Cancer Res. 21, 5601–5611 (2015)CrossRefPubMed
24.
go back to reference E.S. Arnér, A. Holmgren, Physiological functions of thioredoxin and thioredoxin reductase. Eur. J. Biochem. 267, 6102–6109 (2000)CrossRefPubMed E.S. Arnér, A. Holmgren, Physiological functions of thioredoxin and thioredoxin reductase. Eur. J. Biochem. 267, 6102–6109 (2000)CrossRefPubMed
25.
go back to reference J.J. Duan, J. Cai, Y.F. Guo, X.W. Bian, S.C. Yu, ALDH1A3, a metabolic target for cancer diagnosis and therapy. Int. J. Cancer 139, 965–975 (2016)CrossRefPubMed J.J. Duan, J. Cai, Y.F. Guo, X.W. Bian, S.C. Yu, ALDH1A3, a metabolic target for cancer diagnosis and therapy. Int. J. Cancer 139, 965–975 (2016)CrossRefPubMed
26.
go back to reference M. Fukuda, S. Asano, T. Nakamura, M. Adachi, M. Yoshida, M. Yanagida, E. Nishida, CRM1 is responsible for intracellular transport mediated by the nuclear export signal. Nature 390, 308–311 (1997)CrossRefPubMed M. Fukuda, S. Asano, T. Nakamura, M. Adachi, M. Yoshida, M. Yanagida, E. Nishida, CRM1 is responsible for intracellular transport mediated by the nuclear export signal. Nature 390, 308–311 (1997)CrossRefPubMed
27.
go back to reference K. Van Impe, T. Hubert, V. De Corte, B. Vanloo, C. Boucherie, J. Vandekerckhove, J. Gettemans, A new role for nuclear transport factor 2 and ran: Nuclear import of CapG. Traffic 9, 695–707 (2008)CrossRefPubMed K. Van Impe, T. Hubert, V. De Corte, B. Vanloo, C. Boucherie, J. Vandekerckhove, J. Gettemans, A new role for nuclear transport factor 2 and ran: Nuclear import of CapG. Traffic 9, 695–707 (2008)CrossRefPubMed
29.
go back to reference M. Garg, D. Kanojia, A. Mayakonda, T.S. Ganesan, B. Sadhanandhan, S. Suresh, R.P. Nagare, J.W. Said, N.B. Doan, L.W. Ding, E. Baloglu, S. Shacham, M. Kauffman, H.P. Koeffler, Selinexor (KPT-330) has antitumor activity against anaplastic thyroid carcinoma in vitro and in vivo and enhances sensitivity to doxorubicin. Sci. Rep. 7(9749), 9749 (2017)CrossRefPubMedPubMedCentral M. Garg, D. Kanojia, A. Mayakonda, T.S. Ganesan, B. Sadhanandhan, S. Suresh, R.P. Nagare, J.W. Said, N.B. Doan, L.W. Ding, E. Baloglu, S. Shacham, M. Kauffman, H.P. Koeffler, Selinexor (KPT-330) has antitumor activity against anaplastic thyroid carcinoma in vitro and in vivo and enhances sensitivity to doxorubicin. Sci. Rep. 7(9749), 9749 (2017)CrossRefPubMedPubMedCentral
30.
go back to reference J. Yang, M.A. Bill, G.S. Young, K. La Perle, Y. Landesman, S. Shacham, M. Kauffman, W. Senapedis, T. Kashyap, J.R. Saint-Martin, K. Kendra, G.B. Lesinski, Novel small molecule XPO1/CRM1 inhibitors induce nuclear accumulation of TP53, phosphorylated MAPK and apoptosis in human melanoma cells. PLoS One 9, e102983 (2014)CrossRefPubMedPubMedCentral J. Yang, M.A. Bill, G.S. Young, K. La Perle, Y. Landesman, S. Shacham, M. Kauffman, W. Senapedis, T. Kashyap, J.R. Saint-Martin, K. Kendra, G.B. Lesinski, Novel small molecule XPO1/CRM1 inhibitors induce nuclear accumulation of TP53, phosphorylated MAPK and apoptosis in human melanoma cells. PLoS One 9, e102983 (2014)CrossRefPubMedPubMedCentral
32.
go back to reference G. Sun, E. Guzman, V. Balasanyan, C.M. Conner, K. Wong, H.R. Zhou, K.S. Kosik, D.J. Montell, A molecular signature for anastasis, recovery from the brink of apoptotic cell death. J. Cell Biol. 216, 3355–3368 (2017)CrossRefPubMedPubMedCentral G. Sun, E. Guzman, V. Balasanyan, C.M. Conner, K. Wong, H.R. Zhou, K.S. Kosik, D.J. Montell, A molecular signature for anastasis, recovery from the brink of apoptotic cell death. J. Cell Biol. 216, 3355–3368 (2017)CrossRefPubMedPubMedCentral
33.
go back to reference S. Asthana, S. Chauhan, S. Labani, Breast and cervical cancer risk in India: An update. Indian J. Public Health 58, 5 (2014)CrossRefPubMed S. Asthana, S. Chauhan, S. Labani, Breast and cervical cancer risk in India: An update. Indian J. Public Health 58, 5 (2014)CrossRefPubMed
34.
go back to reference X. Gào, B. Schöttker, Reduction–oxidation pathways involved in cancer development: A systematic review of literature reviews. Oncotarget 8(51888) (2017) X. Gào, B. Schöttker, Reduction–oxidation pathways involved in cancer development: A systematic review of literature reviews. Oncotarget 8(51888) (2017)
35.
go back to reference A. Fernández-Medarde, E. Santos, Ras in cancer and developmental diseases. Genes & Cancer 2, 344–358 (2011)CrossRef A. Fernández-Medarde, E. Santos, Ras in cancer and developmental diseases. Genes & Cancer 2, 344–358 (2011)CrossRef
36.
go back to reference M. El-Tanani, E.H. Dakir, B. Raynor, R. Morgan, Mechanisms of nuclear export in cancer and resistance to chemotherapy. Cancers 8, E 35 (2016) M. El-Tanani, E.H. Dakir, B. Raynor, R. Morgan, Mechanisms of nuclear export in cancer and resistance to chemotherapy. Cancers 8, E 35 (2016)
37.
go back to reference G.L. Gravina, W. Senapedis, D. McCauley, E. Baloglu, S. Shacham, C. Festuccia, Nucleo-cytoplasmic transport as a therapeutic target of cancer. J. Hematol. Oncol. 7(85), 85 (2014)CrossRefPubMedPubMedCentral G.L. Gravina, W. Senapedis, D. McCauley, E. Baloglu, S. Shacham, C. Festuccia, Nucleo-cytoplasmic transport as a therapeutic target of cancer. J. Hematol. Oncol. 7(85), 85 (2014)CrossRefPubMedPubMedCentral
38.
go back to reference Y.M. Chook, K.E. Süel, Nuclear import by karyopherin-βs: Recognition and inhibition. Biochim. Biophys. Acta 1813, 1593–1606 (2011)CrossRefPubMed Y.M. Chook, K.E. Süel, Nuclear import by karyopherin-βs: Recognition and inhibition. Biochim. Biophys. Acta 1813, 1593–1606 (2011)CrossRefPubMed
39.
go back to reference S.C. Mutka, W.Q. Yang, S.D. Dong, S.L. Ward, D.A. Craig, P.B. Timmermans, S. Murli, Identification of nuclear export inhibitors with potent anticancer activity in vivo. Cancer Res. 69, 510–517 (2009)CrossRefPubMedPubMedCentral S.C. Mutka, W.Q. Yang, S.D. Dong, S.L. Ward, D.A. Craig, P.B. Timmermans, S. Murli, Identification of nuclear export inhibitors with potent anticancer activity in vivo. Cancer Res. 69, 510–517 (2009)CrossRefPubMedPubMedCentral
40.
go back to reference Y. Chen, S.C. Camacho, T.R. Silvers, A.R. Razak, N.Y. Gabrail, J.F. Gerecitano, E. Kalir, E. Pereira, B.R. Evans, S.J. Ramus, F. Huang, N. Priedigkeit, E. Rordriguez, M. Donovan, F. Khan, T. Kalir, R. Sebra, A. Uzilov, R. Chen, R. Sinha, R. Hm, J.N. Alpert, S. Billaud, D. Shacham, Y. McCauley, T. Landesman, M. Rashal, M.R. Kauffman, M. mirza, P. Mau-Sørensen, J. Dottino, A. Martignetti, Inhibition of the nuclear export receptor XPO1 as a therapeutic target for platinum-resistant ovarian cancer. Clin. Cancer Res. 23, 1552–1563 (2017)CrossRefPubMed Y. Chen, S.C. Camacho, T.R. Silvers, A.R. Razak, N.Y. Gabrail, J.F. Gerecitano, E. Kalir, E. Pereira, B.R. Evans, S.J. Ramus, F. Huang, N. Priedigkeit, E. Rordriguez, M. Donovan, F. Khan, T. Kalir, R. Sebra, A. Uzilov, R. Chen, R. Sinha, R. Hm, J.N. Alpert, S. Billaud, D. Shacham, Y. McCauley, T. Landesman, M. Rashal, M.R. Kauffman, M. mirza, P. Mau-Sørensen, J. Dottino, A. Martignetti, Inhibition of the nuclear export receptor XPO1 as a therapeutic target for platinum-resistant ovarian cancer. Clin. Cancer Res. 23, 1552–1563 (2017)CrossRefPubMed
41.
go back to reference A.S. Azmi, Unveiling the role of nuclear transport in epithelial-to-mesenchymal transition. Curr. Cancer Drug Targets 13, 906–914 (2013)CrossRefPubMed A.S. Azmi, Unveiling the role of nuclear transport in epithelial-to-mesenchymal transition. Curr. Cancer Drug Targets 13, 906–914 (2013)CrossRefPubMed
42.
43.
go back to reference C. Ginestier, M.H. Hur, E. Charafe-Jauffre, F. Monville, J. Dutcher, M. Brown, J. Jacquemier, P. Viens, C.G. Kleer, S. Liu, A. Schott, D. Hayes, D. Birnbaum, M.S. Wicha, G. Dontu, ALDH1 is a marker of normal and malignant human mammary stem cells and a predictor of poor clinical outcome. Cell Stem Cell 1, 555–567 (2007)CrossRefPubMedPubMedCentral C. Ginestier, M.H. Hur, E. Charafe-Jauffre, F. Monville, J. Dutcher, M. Brown, J. Jacquemier, P. Viens, C.G. Kleer, S. Liu, A. Schott, D. Hayes, D. Birnbaum, M.S. Wicha, G. Dontu, ALDH1 is a marker of normal and malignant human mammary stem cells and a predictor of poor clinical outcome. Cell Stem Cell 1, 555–567 (2007)CrossRefPubMedPubMedCentral
Metadata
Title
Molecular profiling of anastatic cancer cells: potential role of the nuclear export pathway
Authors
Mahendra Seervi
S. Sumi
Aneesh Chandrasekharan
Abhay K. Sharma
T. R. SanthoshKumar
Publication date
01-10-2019
Publisher
Springer Netherlands
Published in
Cellular Oncology / Issue 5/2019
Print ISSN: 2211-3428
Electronic ISSN: 2211-3436
DOI
https://doi.org/10.1007/s13402-019-00451-1

Other articles of this Issue 5/2019

Cellular Oncology 5/2019 Go to the issue
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine